Bilyana Stoilova
PhD, MSc, BSc
Senior Clinical Trials Project Manager
I joined OVG in December 2021 as a Project manager to ensure that the clinical trials are delivered on time, within budget and in compliance with the regulatory requirements. I manage the set up and delivery of non-commercial and commercial, University of Oxford- or externally-sponsored, adult and paediatric vaccine clinical trials.
Before joining OVG, from 2008 till 2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany.
After completing my PhD, I worked as a postdoctoral researcher at Prof Paresh Vyas research group Biology and Treatment of Human Myeloid Cancers at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. I worked on research projects aiming to understand the mechanisms of blood cell development and how these mechanisms get deregulated in leukaemia.
Recent publications
-
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Journal article
Aksöz M. et al, (2024), Sci Immunol, 9
-
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Journal article
Jakobsen NA. et al, (2024), Cell Stem Cell
-
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
-
Identification and Age-dependent Increase of Platelet Biased Human Hematopoietic Stem Cells
Preprint
Aksöz M. et al, (2022)
-
Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
Conference paper
Jakobsen NA. et al, (2022), BLOOD, 140, 2227 - 2228